Novavax to participate with in University of Oxford Com-COV3 study comparing mixed COVID-19 Vaccine schedule

Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, is one of the three COVID-19 vaccines that will be studied in adolescents to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.

"Expanding our understanding of how different COVID-19 vaccines can be used to implement flexible vaccine programs across all age groups will be vital to ultimately controlling the pandemic," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "A mixed vaccination series could offer the potential to maximize the use of existing vaccine supply, increase the total number of individuals who can ultimately be vaccinated and accelerate rapid and equitable access across the globe."

Com-COV3 will include at least 360 adolescents 12-16 years of age. Volunteers will receive an authorized vaccine as a first dose and then at least 8 weeks later will receive one of three different vaccines as a second dose. All participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the same vaccine given for the first dose, a full dose of the Novavax vaccine or a half dose of a different authorized vaccine. The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

Under the protocol, participants will be followed for reactogenicity (safety) and immune responses. Results from the study are expected within a few months. The UK Medicines and Healthcare products Regulatory Agency (MHRA) and Joint Committee on Vaccination and Immunisation (JCVI) will formally assess the safety and efficacy of any new vaccination process before advising whether it is rolled out.

Novavax is also participating in University of Oxford's Com-COV2 study, in which NVX-CoV2373 is one of four COVID-19 vaccines being studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. Results from Com-COV2 are expected in the coming weeks. Additional information is available via the study website www.comcovstudy.org.uk.